首页 > 抗体蛋白 > 抗体
PerCP/Cyanine5.5 anti-mouse CD80 Antibody
产品名称:
PerCP/Cyanine5.5 anti-mouse CD80 Antibody
产品类别:
抗体
产品编号:
104721
产品应用:
104721
[价格]
规格 价格 库存
25µg ¥ 1652 1

产品详情

Product Details

Verified Reactivity
Mouse
Reported Reactivity
Dog
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
CHO cell line transfected with mouse B7 (CD80)
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =1.0 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation2, in vitro and in vivo blocking of CTLA-4 Ig to CD80 by blocking costimulation of T cells by activated B cells2-4, and immunohistochemical staining of acetone-fixed frozen sections1,4. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. Nos. 104747-104752).

Additional Product Notes
BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Harlan DM, et al. 1994. P. Natl. Acad. Sci. USA 91:3137. (IHC)
  2. Razi-Wolf Z, et al. 1992. P. Natl. Acad. Sci. USA 89:4210. (Block, IP)
  3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
  4. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
  5. Ma XT, et al. 2006. Cancer Res. 66:1169.
  6. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC)
  7. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  8. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
  9. Misra RS, et al. 2010. J. Exp Med. 207:1775. PubMed
  10. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  11. Philipsen L, et al. 2013. Mol Cell Proteomics. 12:2551. PubMed
Product Citations
  1. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  2. Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed
  3. Miller CM, et al. 2020. J Virol. 94:00:00. PubMed
  4. Luger R, et al. 2013. PLoS One. 8:e54879. PubMed
  5. Taylor J, et al. 2012. J Exp Med. 209:2065. PubMed
  6. Sepe JJ, et al. 2022. JACC Basic Transl Sci. 7:915. PubMed
  7. Pack AD, et al. 2021. Cell Reports. 36(8):109586. PubMed
  8. Li C, et al. 2022. Theranostics. 12:4581. PubMed
  9. Zhao J, et al. 2022. J Nanobiotechnology. 20:62. PubMed
  10. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  11. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  12. Collinson-Pautz M, et al. 2016. PLoS One. 11:e0164547. PubMed
  13. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  14. Khiew SH, et al. 2020. J Clin Invest. 130:3453. PubMed
  15. Olgu?n-Alor R, et al. 2016. PLoS One. 11:e0167813. PubMed
  16. Alves C, et al. 2015. PLoS One. 10: 0142972. PubMed
  17. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  18. Xiong H, et al. 2021. Theranostics. 11:1594. PubMed
  19. Li H, et al. 2020. Nature. 584:274. PubMed
  20. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  21. Argüello RJ, et al. 2018. J Cell Sci. 131:jcs214346. PubMed
  22. Lebel M?, et al. 2020. Nat Commun. 3.051388889. PubMed
  23. Xiao Y, et al. 2022. Nat Commun. 13:758. PubMed
  24. Zhao L, et al. 2021. STAR Protocols. 2(3):100732. PubMed
  25. Zhao F et al. 2018. Immunity. 48(1):147-160 . PubMed
  26. Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed
  27. Liu P, et al. 2020. Mol Cell. 748:77. PubMed
  28. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  29. Darling R, et al. 2020. Int J Nanomedicine. 5.19375. PubMed
  30. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  31. Lopes N, et al. 2022. Elife. 11:. PubMed
  32. Wallner S, et al. 2013. PLoS One. 8:65178. PubMed
  33. Mellal K, et al. 2019. Sci Rep. 9:12903. PubMed
  34. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
RRID
AB_893406 (BioLegend Cat. No. 104721) AB_2291392 (BioLegend Cat. No. 104722)

Antigen Details

Structure
Ig superfamily, 60 kD
Distribution

Macrophages, activated B cells and T cells, dendritic cells

Function
T cell costimulation
Ligand/Receptor
CD28 (stimulatory), CD152(CTLA4) (inhibitory)
Cell Type
B cells, Dendritic cells, Macrophages, T cells, Tregs
Biology Area
Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Linsley PS, et al. 1991. J. Exp. Med. 174:561.
3. Salomon B, et al. 2001. Annu. Rev. Immunol. 19:225.

Gene ID
12519 View all products for this Gene ID
UniProt
View information about CD80 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线